Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants with Heart Failure with Preserved Ejection Fraction and Left Ventricular Hypertrophy.
NN6706-8212
Phase 2 other active
Quick answer
Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants with Heart Failure with Preserved Ejection Fraction and Left Ventricular Hypertrophy. for Heart Failure with Preserved Ejection Fraction and Left Ventricular Hypertrophy. is a Phase 2 program (other) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novo Nordisk A/S
- Indication
- Heart Failure with Preserved Ejection Fraction and Left Ventricular Hypertrophy.
- Phase
- Phase 2
- Modality
- other
- Status
- active